Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Bristol-Myers Squibb (BMY) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY26 Guidance
February 5, 2026 7:00 AM ESTBristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $1.26, $0.14 better than the analyst estimate of $1.12. Revenue for the quarter came in at $12.5 billion versus the consensus estimate of $12.24 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2026 EPS of $6.05-$6.35, versus the consensus of $6.02.... More
